Stay updated on Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page.

Latest updates to the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.1%

- Check23 days agoChange DetectedPublications section updated from 'No Results Posted' to 'Results Submitted', with an explanatory note that PubMed-listed publications are automatically filled from PubMed and may not be about the study.SummaryDifference0.2%

- Check30 days agoChange DetectedRemoved the government funding lapse notice from the page. This is an administrative update that does not pertain to the study details.SummaryDifference0.4%

- Check44 days agoChange DetectedPublications section updated with the 2025 Blood Advances article detailing the phase 2 trial of ibrutinib and nivolumab in relapsed CNS lymphoma. The study record shows a last update posted on 2025-02-28.SummaryDifference0.4%

- Check72 days agoChange DetectedMajor update to the page content: a government-operating status notice and a new version tag (v3.2.0) replacing v3.1.0.SummaryDifference3%

- Check80 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0, signaling a new release. If there were more substantive content changes, they are not present here.SummaryDifference0.1%

Stay in the know with updates to Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page.